ArticleTherapeutics and clinical risk management2011

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor.

Ayad K AliPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.